Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Rigel Pharmaceuticals (NASDAQ: RIGL) was $0.99 for the day, down -16.61% from the previous closing price of $1.19. In other words, the price has decreased by -$16.61 from its previous closing price. On the day, 3.54 million shares were traded. RIGL stock price reached its highest trading level at $1.125 during the session, while it also had its lowest trading level at $0.98.
Ratios:
Our analysis of RIGL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.26.
Piper Sandler Downgraded its Overweight to Neutral on June 08, 2022, whereas the target price for the stock was revised from $7 to $1.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 05 ’24 when RODRIGUEZ RAUL R sold 30,545 shares for $1.14 per share. The transaction valued at 34,821 led to the insider holds 2,036,629 shares of the business.
Santos David A sold 8,918 shares of RIGL for $10,167 on Feb 05 ’24. The EVP, Chief Commercial Officer now owns 349,093 shares after completing the transaction at $1.14 per share. On Feb 05 ’24, another insider, Schorno Dean L, who serves as the EVP & Chief Financial Officer of the company, sold 7,027 shares for $1.14 each. As a result, the insider received 8,011 and left with 402,891 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RIGL now has a Market Capitalization of 174054368. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.45.
Stock Price History:
Over the past 52 weeks, RIGL has reached a high of $1.96, while it has fallen to a 52-week low of $0.71. The 50-Day Moving Average of the stock is -24.29%, while the 200-Day Moving Average is calculated to be -15.82%.
Shares Statistics:
RIGL traded an average of 1.49M shares per day over the past three months and 1691650 shares per day over the past ten days. A total of 174.83M shares are outstanding, with a floating share count of 172.04M. Insiders hold about 1.90% of the company’s shares, while institutions hold 60.79% stake in the company. Shares short for RIGL as of 1713139200 were 5166554 with a Short Ratio of 3.46, compared to 1710460800 on 4944612. Therefore, it implies a Short% of Shares Outstanding of 5166554 and a Short% of Float of 3.01.
Earnings Estimates
The company has 6.0 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.02 for the current quarter, with a high estimate of $0.0 and a low estimate of -$0.03, while EPS last year was -$0.04. The consensus estimate for the next quarter is -$0.05, with high estimates of $0.02 and low estimates of -$0.09.
Analysts are recommending an EPS of between $0.04 and -$0.13 for the fiscal current year, implying an average EPS of -$0.06. EPS for the following year is $0.09, with 6.0 analysts recommending between $0.18 and -$0.02.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $34.2M to a low estimate of $31.56M. As of the current estimate, Rigel Pharmaceuticals’s year-ago sales were $26.89MFor the next quarter, 5 analysts are estimating revenue of $37.63M. There is a high estimate of $45.2M for the next quarter, whereas the lowest estimate is $32.31M.
A total of 5 analysts have provided revenue estimates for RIGL’s current fiscal year. The highest revenue estimate was $160.2M, while the lowest revenue estimate was $136.4M, resulting in an average revenue estimate of $148.99M. In the same quarter a year ago, actual revenue was $116.88MBased on 6 analysts’ estimates, the company’s revenue will be $192.17M in the next fiscal year. The high estimate is $217.4M and the low estimate is $160M.
